ClinicalTrials.gg
CompletedNCT01050582Updated Nov 27, 2012Results posted

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

A Phase 4 interventional study of Risperidone and Other atypical antipsychotic drugs in Schizophrenia, Bipolar Disorder and Autistic Disorder, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 29 sites in 6 countries. Open to participants aged 8 Years to 16 Years. Per ClinicalTrials.gov, last updated 2012-11-27.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
244
Ages
8 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
29th of 123
244 · median 100
Started
2009
with 3 others
Phase 4
63 of 127
2 open now
Registered
77th of 127
by date
Lead sponsor
12 of 127
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 127 studies testing risperidone in Schizophrenia, this one is the 29th largest by enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2009, is one of 63 in phase 4, and was the 77th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 8 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events (side effects) associated to these drugs.

Read the detailed description

This is a study to find out what the effects are of long-term use of atypical antipsychotics (drugs used to treat mental health and some behavior disorders) in children and adolescents on their growth and physical maturity. Atypical antipsychotics are used in the treatment of a wide range of disorders in children and adolescents, such as; schizophrenia, bipolar mania, autistic disorder or other disruptive behavior disorders. This study does not involve using any new medication, but to look into some of the side effects that children and adolescents may experience from taking an atypical antipsychotic. One of the side effects of some atypical antipsychotics is an increased level of "prolactin", a hormone that occurs naturally in the body which can lead to "hyperprolactinemia" a condition in which the pituitary gland produces too much prolactin. In order to further investigate these possible side effects, two groups of children and adolescents (aged 8 to 16) with a diagnosis of schizophrenia, bipolar mania, autistic disorder, or conduct and other disruptive behavior disorders who are or have been recently treated with an atypical antipsychotic will be enrolled; 1 group of children and adolescents will either be currently taking or have recently been treated with risperidone and the second group of children and adolescents will either be currently taking or have recently been treated with an a similar type of atypical antipsychotic therapy. The results will then be compared to see if the age of physical maturation, growth and development differs between the two groups, using data collected during an office visit and previous information available from existing medical records. The patient's growth will be assessed using information on height and weight taken from the medical records at different time points before (up to one year previous) and since they started treatment with antipsychotic therapy. In addition, there will also be one visit to the clinic where the growth and stage of sexual maturity of the patient will be reviewed by both the study doctor and through the patient's own assessment, using a questionnaire and pictures developed specially to assess stages of physical development (so called - Tanner stage). In addition, one blood sample will be taken from each patient to check the levels of prolactin hormone in the blood to see if this differs between treatment groups. Potential patients will be identified through automated databases and/or medical chart review. If, after fully understanding the purpose of this study, the parent, legal guardian and their child agree to participate by signing an informed consent (children to sign an assent form), information (specified below) related to your child's treatment and development will be collected directly from central medical records or from notes kept by your child's doctor for evaluation. The following data will be collected from available medical records: information about the patient's use of antipsychotic drug and prescriptions; previous records of the patient's height, weight, and growth; physical and sexual development (so called, Tanner stage [developmental stage]) if available; results of previous blood tests taken to evaluate the level of the hormone prolactin if available; and, history of any side effects that could be related to increased levels of the hormone prolactin. All the above information will be collected within 1 year before the patient started antipsychotic therapy. The same information (if available) will also be collected following the time that the patient starting taking their atypical antipsychotic medication until the present time. As much information as possible will be collected for this period of time so that a determination of how taking antipsychotic drugs may have influenced the patient's growth can be made. The study doctor will see each patient for a single study visit. This visit will take place at a convenient time approximately one week after informed consent/assent has been obtained. At the clinic visit, the study doctor will do some examinations to check the patient's general health and assess their growth and physical development. These will include: a physical examination (including developmental stage assessment [Tanner stage]), weight and height, vital signs (pulse, respiration rate, temperature and blood pressure), medical history, and the collection of information regarding the occurrence of any side effects thought to be related to the use of atypical antipsychotic medication or related to the hormone prolactin. In addition to being assessed by the study doctor, the patient will be asked to complete the Tanner Stage questionnaire. This will involve the patient reviewing both pictures and written descriptions of children at different stages of physical development. The patient will have to decide which picture/description is most representative of their body. The study doctor will also look at the patient's current use of any other medications. Each patient will participate in the study for about one week. The outcome measures of the study will be to compare Z-scores for height, age at current Tanner stage, and prolactin-related adverse events between patients exposed to risperidone and patients exposed to other atypical antipsychotic drugs. Outcome measures will be collected during the study visit and retrospectively during the time of exposure for up to 2 years prior to the study visit.

03

Conditions studied

  • Schizophrenia
  • Bipolar Disorder
  • Autistic Disorder
  • Conduct and Other Disruptive Behavior Disorders

Keywords

  • Schizophrenia
  • Bipolar Disorder
  • Autistic Disorder
  • Conduct and Other Disruptive Behavior Disorders
  • Risperidone
  • RISPERDAL
  • Antipsychotic Agents
  • Prolactin
  • Pediatrics
04

Who can participate

Ages eligible
8 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • One or both parents (according to local regulations) or a guardian must have signed an document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study (If appropriate according to local regulations, the patient must also assent)
  • Treated for schizophrenia, bipolar mania, autistic disorder, or conduct and other disruptive behavior disorders
  • Had at least 6 months of exposure for an atypical antipsychotic drug within 24 months before the study visit (patients may or may not be taking the atypical antipsychotics at the time of actual enrollment, eligible patients can have exposure to multiple atypical antipsychotics, however, they cannot concomitantly be exposed to more than 1 atypical antipsychotic for a period of greater than 30 days)
  • Had medical records or automated data available for at least 1 year prior to the start of exposure
  • Height and weight were recorded at least once within 1 year before the start of exposure, and if available at any time points after the start of exposure in the medical records or electronic databases (not mandatory)

Exclusion criteria

Exclusion Criteria:

  • Have at least 1 medical record, at any time before the start of exposure, consistent with (other than non-melanoma skin cancer), pregnancy, or a developmental delay or abnormality associated with growth or sexual maturation delays not related to the specified indications
  • Had exposure to prolactin elevating medications other than atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs)
  • Had exposure to Paliperidone
  • Cannot comply with study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    Risperidone

    Risperidone as per local prescribing practices

    Drug: Risperidone

  • Experimental
    Other atypical antipsychotic drugs

    Other atypical antipsychotic drugs as per local prescribing practices

    Drug: Other atypical antipsychotic drugs

Interventions

  • As per local prescribing practices

  • DrugOther atypical antipsychotic drugs

    As per local prescribing practices

06

What researchers measure

Primary outcomes

  1. Height (cm) Z-score at Study Visit

    Height (cm) measured at the study visit was converted to a Z-score based on the US Center for Disease Control 2000 growth charts for US subjects and European growth charts for ex-US subjects. A z-score indicates how many standard deviations a subject is away from the expected height for the subject's age and gender.

    Time frame: One single study visit, approximately one week after informed consent has been obtained

Secondary outcomes

  1. Age (Years) at Current Tanner Stage

    Tanner stage is an evaluation of pubertal development with values ranging from 1 (pre-pubertal) to 5 (adult). A standardized, validated tool containing standardized pictures and written descriptions of the stages of pubic hair development, breast development for girls, and genital development for boys was used by physicians to make their assessment.

    Time frame: One single study visit, approximately one week after informed consent has been obtained

  2. Number of Participants With Retrospectively Reported Potentially Prolactin-Related Adverse Events

    Previous potentially prolactin-related adverse events, including hyperprolactinemia, were reviewed and abstracted from participants' medical records. Potentially prolactin-related adverse events include breast symptoms, menstrual disorders, hyperprolactinemia, and prolactinoma.

    Time frame: Retrospectively during the time of exposure for up to 2 years prior to the study visit

07

Results

Posted Nov 27, 2012
Limitations and caveats
A total of 350 subjects in a 1:1 ratio between the two arms was planned. Recruitment difficulties led to an imbalance in the number of subjects per arm and to early termination of the study. The results should be interpreted within this context.

Participant flow

A total of 244 subjects were assessed for eligibility of whom 230 signed informed consent. Of the 230, 43 were found not to meet inclusion or exclusion criteria, 2 withdrew consent, and 1 was not kept in the study due to a site decision. A total of 184 subjects were included in the analysis.

Participant flow — Overall Study
MilestoneRisperidoneOther Atypical Antipsychotics
Started13351
Completed13351
Not completed00

Outcome measures

PrimaryHeight (cm) Z-score at Study Visit

Height (cm) measured at the study visit was converted to a Z-score based on the US Center for Disease Control 2000 growth charts for US subjects and European growth charts for ex-US subjects. A z-score indicates how many standard deviations a subject is away from the expected height for the subject's age and gender.

Time frame:
One single study visit, approximately one week after informed consent has been obtained
Reported as:
Mean · z-score
Height (cm) Z-score at Study Visit
z-scoreRisperidoneOther Atypical Antipsychotics
Height (cm) Z-score at Study Visit0.40 ± 1.1890.09 ± 1.079
Statistical analysis
  • Risperidone vs Other Atypical Antipsychotics · Regression, Linear · p = <0.001 · Slope: 0.447 · 95% CI 0.220 to 0.674Slope associated with treatment dummy variable with 1 indicating risperidone and 0 indicating other atypical antipychotics.
SecondaryAge (Years) at Current Tanner Stage

Tanner stage is an evaluation of pubertal development with values ranging from 1 (pre-pubertal) to 5 (adult). A standardized, validated tool containing standardized pictures and written descriptions of the stages of pubic hair development, breast development for girls, and genital development for boys was used by physicians to make their assessment.

Time frame:
One single study visit, approximately one week after informed consent has been obtained
Reported as:
Mean · years
Age (Years) at Current Tanner Stage
yearsRisperidoneOther Atypical Antipsychotics
Tanner Stage 110.2 ± 1.3110.3 ± 1.78
Tanner Stage 211.3 ± 1.6811.2 ± 1.73
Tanner Stage 313.1 ± 2.1812.2 ± 1.21
Tanner Stage 414.9 ± 1.2715.0 ± 1.46
Tanner Stage 515.1 ± 0.6915.0 ± 1.82
Statistical analysis
  • Risperidone vs Other Atypical Antipsychotics · Regression, Linear · p = 0.378 · Slope: -0.221 · 95% CI -0.711 to 0.269Slope associated with treatment dummy variable with 1 indicating risperidone and 0 indicating other atypical antipsychotics.
SecondaryNumber of Participants With Retrospectively Reported Potentially Prolactin-Related Adverse Events

Previous potentially prolactin-related adverse events, including hyperprolactinemia, were reviewed and abstracted from participants' medical records. Potentially prolactin-related adverse events include breast symptoms, menstrual disorders, hyperprolactinemia, and prolactinoma.

Time frame:
Retrospectively during the time of exposure for up to 2 years prior to the study visit
Reported as:
Number · participants
Number of Participants With Retrospectively Reported Potentially Prolactin-Related Adverse Events
participantsRisperidoneOther Atypical Antipsychotics
Number of Participants With Retrospectively Reported Potentially Prolactin-Related Adverse Events73
Statistical analysis
  • Risperidone vs Other Atypical Antipsychotics · Fisher Exact · p = >0.999 · Odds ratio (or): 0.865 · 95% CI 0.189 to 3.963Estimated OR is from a logistic regression model including factors for treatment arm, age, indication, and use of concomitant medication with growth effects.

Adverse events

Collected over Days from signing of informed consent to study visit. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risperidone—0/133 (0%)8/133 (6%)
Other Atypical Antipsychotics—0/51 (0%)3/51 (5.9%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventRisperidoneOther Atypical Antipsychotics
FatigueGeneral disorders1/1331/51
Breast painReproductive system and breast disorders0/1331/51
Lower respiratory tract infectionInfections and infestations0/1331/51
NasopharyngitisInfections and infestations0/1331/51
Blood prolactin increasedInvestigations1/1330/51
Eye infectionInfections and infestations1/1330/51
SedationNervous system disorders1/1330/51
HeadacheNervous system disorders1/1330/51
Middle insomniaPsychiatric disorders1/1330/51
Weight increasedInvestigations1/1330/51

Baseline characteristics

Age Continuous
Age Continuous(years)RisperidoneOther Atypical AntipsychoticsTotal
Mean12 ± 2.512 ± 2.512 ± 2.5
Sex: Female, Male
Sex: Female, Male(Participants)RisperidoneOther Atypical AntipsychoticsTotal
Female161834
Male11733150
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RisperidoneOther Atypical AntipsychoticsTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American12618
White11036146
More than one race314
Unknown or Not Reported7714
Region of Enrollment
Region of Enrollment(participants)RisperidoneOther Atypical AntipsychoticsTotal
United States594099
Germany41647
Poland19322
Netherlands808
Greece325
Belgium303
08

Study locations

29 sites
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Altamonte Springs, Florida, United States
  • Gainesville, Florida, United States
  • Smyrna, Georgia, United States
  • Naperville, Illinois, United States
  • Indianapolis, Indiana, United States
  • Valparaiso, Indiana, United States
  • Boston, Massachusetts, United States
  • Cambridge, Massachusetts, United States
  • Glen Oaks, New York, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Antwerpen, Belgium
  • Freiburg, Germany
  • Jena, Germany
  • Mannheim, Germany
  • München, Germany
  • Tübingen, Germany
  • Ulm, Germany
  • Würzburg, Germany
  • Athens, Greece
  • Nijmegen, Netherlands
  • Gdansk, Poland
  • Kielce, Poland
  • Lódź, Poland
  • Sosnowiec, Poland
  • Warszawa N/A, Poland
  • Warszawa, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2010
First posted
Jan 15, 2010
Start
Oct 2009
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Nov 27, 2012
Last update
Nov 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01050582
Responsible party
Sponsor
First posted
Jan 15, 2010
Start date
Oct 2009
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Nov 27, 2012
Last update
Nov 27, 2012

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion